Corrigendum to “the Efficacy and Safety of Ropinirole Prolonged Release Tablets As Adjunctive Therapy in Chinese Subjects with Advanced Parkinson’s Disease: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study” [parkinsonism and Related Disorders 19 (2013) 1022–1026]
Zhenxin Zhang,Jian Wang,Xiaoying Zhang,Shengdi Chen,Zhenfu Wang,Baorong Zhang,Chun‐Feng Liu,Qing Qu,Yan Cheng,Jie Li,Haijun Cao,Meiling Cai,Rongxuan Zhu
DOI: https://doi.org/10.1016/j.parkreldis.2014.03.025
2014-01-01
Abstract:The authors regret that errors have been found in Tables 1 and 2 and its corresponding paragraph within the text. The correct information is shown below, and the authors would like to apologise for any inconvenience caused. 3.2. Primary and secondary efficacy outcomes Hours of total awake time spent “off” were significantly decreased in the ropinirole PR group compared with placebo group (Table 2; Supplemental Figure 1). Hours of “on” time, “on” time without troublesome dyskinesia, were significantly increased, whereas the percent “off” time were significantly decreased for ropinirole PR compared with placebo (Table 2). For primary efficacy variables, similar results were observed for the PP population.Table 1Baseline demographic and clinical characteristics of subjects with Parkinson's disease (Safety population).aUnless noted otherwise, values are expressed as mean SD; PD: Parkinson's disease.Number of subjectsRopinirole PR (n = 175)Placebo (n = 170)Total (n = 345)Age (years)64.1 (9.0)63.6 (10.5)63.9 (9.7)Female, n (%)59 (33.7)65 (38.2)124 (35.9)Height (cm); mean [range]165.4 [145.0–183.0]165.1 [143.0–187.0]165.2 [143.0–187.0]Weight (kg); mean [range]63.9 [43.5–94.0]63.1 [40.0–97.0]63.5 [40.0–97.0]Duration of PD, months92.1 (59.9)95.7 (48.3)93.9 (54.4)Duration of L-dopa, months68.8 (49.2)69.7 (41.7)69.2 (45.6)L-dopa dose (mg/day)506.6 (290.9)539.8 (426.2)522.9 (363.6)Subjects with any concomitant medicines except for L-dopa during treatment period, n (%)153 (87.4)157 (92.4)31 (89.9)Amantadine hydrochloride71 (40.6)68 (40.0)139 (40.3)Selegiline hydrochloride31 (17.7)34 (20.0)65 (18.8)Trihexyphenidyl hydrochloride38 (21.7)24 (14.1)62 (18.0)Entacapone26 (14.9)27 (15.9)53 (15.4)a Unless noted otherwise, values are expressed as mean SD; PD: Parkinson's disease. Open table in a new tab Table 2Mean (SD) change from baseline in awake time spent “off”, awake time spent “on” and total awake time spent “on” without troublesome dyskinesia, UPDRS motor and ADL scores, HAMD-17 and PDSS scales and PDQ-39 domain scores at week 24 last observation carried forward (intention-to-treat population).BaselineWeek 24Change from BaselineAdjusted treatment difference 95% CIp-ValueRopinirole PR (N = 175)Placebo (N = 169)Ropinirole PR (N = 175)Placebo (N = 169)Ropinirole PR (N = 175)Placebo (N = 169)Total awake time spent ‘off’aA decrease from baseline indicates an improvement (h)7.0 (2.89)7.0 (2.90)4.9 (3.05)6.6 (3.25)−2.1 (2.58)−0.4 (2.47)−1.76 (−2.27, −1.26)<0.001Percent awake time spent ‘off’’aA decrease from baseline indicates an improvement45.4 (17.19)45.6 (17.03)31.9 (19.44)43.9 (20.17)−13.5 (15.62)−1.8 (15.88)−11.92 (−15.14, −8.70)<0.001Total awake time spent ‘on’bAn increase from baseline indicates an improvement. (h)8.4 (2.79)8.3 (2.71)10.4 (2.99)8.4 (3.05)1.9 (2.44)0.1 (2.48)1.90 (1.40, 2.40)<0.001Total awake time spent ‘on’ without troublesome dyskinesiabAn increase from baseline indicates an improvement. (h)7.9 (2.99)7.8 (2.90)9.6 (3.29)8.0 (3.28)1.7 (2.81)0.3 (2.56)1.49 (0.94, 2.03)<0.001UPDRS motoraA decrease from baseline indicates an improvement28.8 (13.35)29.3 (12.39)22.6 (12.17)28.6 (13.39)−6.3 (10.08)−0.7 (9.03)−5.66 (−7.53, −3.79)<0.001UPDRS ADLaA decrease from baseline indicates an improvement12.3 (5.81)13.2 (6.23)10.2 (5.16)13.1 (6.11)−2.2 (3.93)−0.2 (3.64)−2.25 (−2.99, −1.51)<0.001HAMD-17aA decrease from baseline indicates an improvement6.4 (4.76)7.9 (5.36)4.8 (4.30)7.3 (5.35)−1.6 (4.38)−0.6 (4.33)−1.66 (−2.48, −0.83)<0.001PDSS scale107.1 (23.25)103.3 (27.2)107.4 (24.52)102.1 (26.91)0.5 (21.22)−1.7 (20.57)3.26 (−0.94, 7.47)0.128PDQ-39 subscalecRopinirole PR n = 170 and placebo n = 160.MobilityaA decrease from baseline indicates an improvement33.9 (22.99)38.8 (24.64)28.4 (22.92)41.0 (25.38)−5.7 (18.10)2.5 (17.30)−9.34 (−12.87, −5.81)<0.001Activities of daily livingaA decrease from baseline indicates an improvement32.2 (22.47)33.8 (22.40)26.1 (21.65)33.2 (24.54)−5.9 (18.20)0.3 (18.95)−6.09 (−9.69, −2.49)<0.001Emotional well-beingaA decrease from baseline indicates an improvement22.0 (19.90)27.0 (20.65)17.3 (17.28)26.0 (20.44)−4.8 (17.37)−0.8 (15.30)−5.82 (−8.94, −2.70)<0.001StigmaaA decrease from baseline indicates an improvement20.9 (22.19)24.5 (24.47)15.9 (20.17)23.6 (24.36)−5.1 (18.01)−1.1 (18.17)−5.25 (−8.79, −1.71)0.004Social supportdRopinirole PR n = 167 and placebo n = 157; UPDSR motor 0–108, 0 = normal/no symptoms, UPDRS ADL, 0–52, 0 = normal no symptoms; PDSS, 15 scales, 0 = symptom severe and always experienced to 10 = symptom free, cumulative score for the PDSS is 150 (subject is free of all symptoms); PDQ-39 scale = 0–100 for each domain and ranged from 0 to 100, where 0 represents no problems and 100 represents the number of problems; UPDRS: Unified Parkinson Disease Rating Scale; ADL: Assisted Daily living; HAMD-17: Hamilton Depression rating Scale-17; PDSS:7.6 (15.64)10.0 (16.90)7.1 (14.23)9.4 (17.13)−0.4 (14.63)−0.7 (15.21)−0.96 (−3.81, 1.89)0.507Cognitive impairment30.8 (18.45)31.4 (19.72)29.9 (17.40)31.0 (20.29)−1.1 (14.36)−0.8 (13.28)−0.48 (−3.23, 2.27)0.731CommunicationsaA decrease from baseline indicates an improvement16.8 (17.29)19.0 (20.93)15.8 (17.66)21.7 (21.44)−1.1 (12.28)2.6 (17.21)−4.29 (−7.31, −1.27)0.006Bodily discomfortaA decrease from baseline indicates an improvement30.3 (24.24)32.1 (23.29)27.0 (21.36)32.0 (22.47)–3.5 (19.16)0.7 (19.15)4.45 (−8.03, −0.87)0.015CI: confidence interval.a A decrease from baseline indicates an improvementb An increase from baseline indicates an improvement.c Ropinirole PR n = 170 and placebo n = 160.d Ropinirole PR n = 167 and placebo n = 157; UPDSR motor 0–108, 0 = normal/no symptoms, UPDRS ADL, 0–52, 0 = normal no symptoms; PDSS, 15 scales, 0 = symptom severe and always experienced to 10 = symptom free, cumulative score for the PDSS is 150 (subject is free of all symptoms); PDQ-39 scale = 0–100 for each domain and ranged from 0 to 100, where 0 represents no problems and 100 represents the number of problems; UPDRS: Unified Parkinson Disease Rating Scale; ADL: Assisted Daily living; HAMD-17: Hamilton Depression rating Scale-17; PDSS: Open table in a new tab CI: confidence interval. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled studyParkinsonism & Related DisordersVol. 19Issue 11PreviewThe first evaluation of the efficacy and safety of ropinirole prolonged release (PR) as an adjunct to L-dopa in Chinese patients with advanced Parkinson's disease (PD) not optimally controlled with L-dopa. Full-Text PDF